600 patients66,869 observations120 daysLIVE
← Patients

Patient P-01521

Synthetic patientNBL-101 · Day 112 · 65–74 · M · baseline S14Steering view · 3DOpen companion preview
Therapy response
Improving
Tolerance
Improving
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
94%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 started — Baseline state S14
  2. Day 81 Trajectory diverged from prediction — Observed response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 81.

Primary contributors, last 14 days
  • GI instability+18
  • Inflammatory activity+10
  • Nutritional resilience-9
  • Toxicity-8
  • Treatment adherence+3

What helped?

No interventions yet.

    LIFE OS recommendation
    GI Support Protocol GI-04
    66%
    probability of meaningful tolerance improvement
    • 284 similar trajectories
    • 83% showed improvement
    • median effect visible after 8 days
    View similar patientsSimulateAdd to intervention cohortAll evidence

    Daily trackers

    Molecule settings

    The trackers this program marks as important, last 14 days vs the 14 before.

    GI burden
    Companion
    71.1/100
    stable · +1.1 vs previous 14 d
    Toxicity
    Blood
    56.1/100
    worsening · +6.4 vs previous 14 d
    Sleep quality
    Wearable
    40.1/100
    stable · -1.1 vs previous 14 d
    Energy level
    Daily log
    1.7/10
    worsening · -0.3 vs previous 14 d
    Stress level
    Daily log
    7.3/10
    stable · +0.2 vs previous 14 d
    Steps
    Wearable
    1,137
    stable · -41 vs previous 14 d
    Adherence
    Companion
    73.4 %
    worsening · -11.1 vs previous 14 d
    This trajectory is decaying — what would help, what would not
    Steering view →

    Heading towards failing · 30 from the failing basin, 73 from restoration.

    Would help
    • GI-04 GI Support Protocol
      73% improved among 124 similar · onset 8 d · confidence 65%
    • ME-01 Monitoring Escalation
      100% improved among 77 similar · onset 3 d · confidence 69%
    • NP-02 Dietary Support Protocol
      63% improved among 64 similar · onset 10 d · confidence 69%
    Would not help
    • Keep histamine low
      GI +4.9 next day on high-intake days · n 23
    • Keep simple carbs low
      GI +4 next day on high-intake days · n 24
    • Keep alcohol low
      GI +2.2 next day on high-intake days · n 17
    State influencers · digestive

    Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

    • Histamine load
      +4.9detractor · 95%
    • Simple carbohydrates
      +4detractor · 95%
    • Alcohol
      +2.2detractor · 60%
    • Dietary fat load
      +1.9no signal · 49%
    • Spicy / capsaicin
      -0.3no signal · 15%
    • Insoluble fibre
      -0.1no signal · 15%

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Inflammatory signalling ↑85
      • DNAIL6 -174 variant raises baseline inflammatory tone
      • MicrobiomeBacteroides fragilis expansion
      • BloodInflammatory load index 66
      • WearableHRV 38 ms, trending down
    • Mucosal barrier integrity ↓80
      • DNAFUT2 non-secretor lowers mucosal fucosylation
      • MicrobiomeAkkermansia low → thinner mucus layer
      • Daily logGI symptom score 71 and rising
    • Autonomic recovery ↓45
      • WearableResting HR 73 bpm
      • Wearable1,137 steps/day
    • Butyrate / short-chain fatty acid production ↓20
      • Daily logFibre intake low in recent food logs
    • Drug metabolism and exposure ↑20
      • BloodToxicity index 56
    DNA
    Fictional pharmacogenomic panel
    • FUT2 rs601338 AA (non-secretor)
      Reduced mucosal fucosylation
    • IL6 -174 G/C
      Higher inflammatory tone
    • CYP2D6 Normal metabolizer
      Expected exposure
    Microbiome
    Shannon diversity 1.9 · butyrate capacity 48/100
    • Akkermansia muciniphilaLow
    • Faecalibacterium prausnitziiNormal
    • Bacteroides fragilisHigh
    • Bifidobacterium longumNormal
    • EnterobacteriaceaeNormal
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    40 ms
    Sleep
    7.2 h
    Steps
    1,431
    Resting HR
    72 bpm
    Daily log: GI score 71, nutritional resilience 30, adherence 73.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
    • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
    • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
    • Avoid known triggers for now: fried or oily food, dairy, alcohol
    What to do
    • Track each bowel movement today: time, stool form, urgency, overnight waking
    • A 15-minute walk after lunch
    • Keep the sleep window steady
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the scheduled dose as agreed with your care team
    • Electrolyte solution, one sachet after any loose stool
    • Fictional demo item: oral nutrition supplement with lunch

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    Sort by similaritySort by interventionSort by outcomeSort by stateSort by response
    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0187740%S01CR-01improved67
    P-0131039%S01——57
    P-0168826%S01GI-04improved40
    P-0132725%S01GI-04improved56
    P-0181325%S01NP-02no change40
    P-0160421%S01——71
    P-0182321%S01——57
    P-0145936%S02——51
    P-0145230%S02GI-04improved46
    P-0163527%S02GI-04improved49
    P-0149821%S02——56
    P-0149921%S02——65